Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Change in Accured Expenses (2016 - 2025)

Historic Change in Accured Expenses for Collegium Pharmaceutical (COLL) over the last 10 years, with Q3 2025 value amounting to -$8.1 million.

  • Collegium Pharmaceutical's Change in Accured Expenses rose 8710.71% to -$8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 10390.89%. This contributed to the annual value of -$39.5 million for FY2024, which is 639458.6% down from last year.
  • According to the latest figures from Q3 2025, Collegium Pharmaceutical's Change in Accured Expenses is -$8.1 million, which was up 8710.71% from $5.6 million recorded in Q2 2025.
  • In the past 5 years, Collegium Pharmaceutical's Change in Accured Expenses registered a high of $22.4 million during Q4 2024, and its lowest value of -$62.9 million during Q3 2024.
  • For the 5-year period, Collegium Pharmaceutical's Change in Accured Expenses averaged around -$3.4 million, with its median value being -$821000.0 (2022).
  • Data for Collegium Pharmaceutical's Change in Accured Expenses shows a peak YoY increase of 163509.32% (in 2025) and a maximum YoY decrease of 277772.73% (in 2025) over the last 5 years.
  • Collegium Pharmaceutical's Change in Accured Expenses (Quarter) stood at $10.8 million in 2021, then increased by 25.76% to $13.6 million in 2022, then tumbled by 62.42% to $5.1 million in 2023, then surged by 339.04% to $22.4 million in 2024, then tumbled by 136.19% to -$8.1 million in 2025.
  • Its Change in Accured Expenses was -$8.1 million in Q3 2025, compared to $5.6 million in Q2 2025 and -$17.7 million in Q1 2025.